Angeion/Medical Graphics
This article was originally published in The Gray Sheet
Executive Summary
Stock swap acquisition of heart and lung disease diagnostic equipment maker Medical Graphics by Angeion is valued at approximately $16.3 mil. Minneapolis-based Angeion will acquire all outstanding shares of Medical Graphics for $2.15 per share under an agreement announced Sept. 23. The merger stems from Angeion's effort since December 1998 to explore strategic alternatives to provide greater shareholder value, including decreasing its presence in the implantable cardioverter defibrillator market. Medical Graphics generated revenues of $20 mil. in 1998 and has 120 employees. President and CEO Richard Jahnke will assume the same titles at Angeion after the merger, and current Angeion President and CEO James Hickey will remain a director. The deal is anticipated to close by year-end
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.